Albiglutide
Albiglutide (GLP-1 Receptor Agonist)
A once-weekly GLP-1 receptor agonist fused to albumin for extended half-life. FDA-approved for type 2 diabetes (Tanzeum/Eperzan) and shown to reduce cardiovascular events.
Mechanism of Action
Albiglutide is a GLP-1 dimer fused to human albumin, providing a 5-day half-life for once-weekly dosing. It activates GLP-1 receptors to improve glycemic control.
Health Claims & Evidence
Improves glycemic control in type 2 diabetes
Reduces cardiovascular risk
Modest weight loss
Short-Term Effects
Improved glycemic control, less nausea than other GLP-1 agonists.
Long-Term Effects
Sustained glycemic control and cardiovascular risk reduction.
Side Effects
Injection site reactions, nausea (less than other GLP-1 agonists).
Contraindications
Avoid with personal/family history of medullary thyroid carcinoma.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Albiglutide and cardiovascular outcomes
Hernandez et al. · Lancet · 2018
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on Albiglutide and related peptides, and prepare an educational research summary.
Explore Research